SSG
GSK icon

Summit Securities Group’s GSK GSK Stock Holding History

Summit Securities Group’s Portfolio GSK Stock Details GSK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.24K Sell
100
-200
-67% -$10.6K ﹤0.01% 967
2026
Q1 		$16.6K Sell
300
-1,900
-86% -$103K ﹤0.01% 555
2025
Q4 		$108K Sell
2,200
-600
-21% -$28K 0.01% 460
2025
Q3 		$121K Buy
+2,800
New +$109K 0.03% 351
2024
Q4 		– Sell
-7,183
Closed -$719K – 746
2024
Q3 		$719K Sell
7,183
-2,332
-25% -$95.4K 0.19% 74
2024
Q2 		$295K Sell
9,515
-25,421
-73% -$1.07M 0.06% 135
2024
Q1 		$1.5M Sell
34,936
-16,900
-33% -$697K 0.25% 52
2023
Q4 		$1.92M Buy
51,836
+5,729
+12% +$206K 0.17% 91
2023
Q3 		$1.67M Buy
46,107
+46,007
+46,007% +$1.63M 0.17% 71
2023
Q2 		$4K Sell
100
-23,328
-100% -$837K ﹤0.01% 824
2023
Q1 		$834K Buy
23,428
+22,148
+1,730% +$775K 0.07% 103
2022
Q4 		$45K Hold
1,280
– – ﹤0.01% 734
2022
Q3 		$38K Sell
1,280
-11,200
-90% -$424K ﹤0.01% 644
2022
Q2 		$679K Buy
12,480
+8,880
+247% +$490K 0.08% 161
2022
Q1 		$196K Sell
3,600
-2,240
-38% -$122K 0.02% 385
2021
Q4 		$322K Buy
+5,840
New +$304K 0.02% 477
2021
Q3 		– Sell
-11,520
Closed -$579K – 776
2021
Q2 		$573K Buy
11,520
+3,520
+44% +$169K 0.05% 355
2021
Q1 		$357K Sell
8,000
-9,320
-54% -$423K 0.04% 408
2020
Q4 		$797K Buy
17,320
+5,000
+41% +$230K 0.07% 267
2020
Q3 		$580K Buy
12,320
+8,240
+202% +$413K 0.06% 210
2020
Q2 		$208K Buy
+4,080
New +$209K 0.03% 389
2020
Q1 		– Sell
-33,600
Closed -$1.79M – 363
2019
Q4 		$1.97M Buy
+33,600
New +$1.87M 0.15% 139
2019
Q3 		– Sell
-13,120
Closed -$675K – 364
2019
Q2 		$656K Buy
+13,120
New +$658K 0.08% 175
2019
Q1 		– Sell
-5,360
Closed -$268K – 267
2018
Q4 		$256K Sell
5,360
-6,720
-56% -$331K 0.02% 261
2018
Q3 		$607K Buy
12,080
+7,120
+144% +$362K 0.23% 71
2018
Q2 		$250K Sell
4,960
-5,280
-52% -$266K 0.04% 190
2018
Q1 		$500K Buy
+10,240
New +$477K 0.12% 86
2016
Q4 		– Sell
-3,840
Closed -$207K – 286
2016
Q3 		$207K Buy
+3,840
New +$211K 0.07% 135
2015
Q3 		– Sell
-1,280
Closed -$66.6K – 421
2015
Q2 		$67K Sell
1,280
-1,440
-53% -$81.1K 0.03% 164
2015
Q1 		$157K Sell
2,720
-1,920
-41% -$110K 0.12% 98
2014
Q4 		$248K Sell
4,640
-2,720
-37% -$152K 0.07% 168
2014
Q3 		$423K Buy
7,360
+2,720
+59% +$167K 0.12% 124
2014
Q2 		$310K Buy
4,640
+2,480
+115% +$168K 0.11% 125
2014
Q1 		$144K Buy
2,160
+1,200
+125% +$81.1K 0.09% 114
2013
Q4 		$64K Buy
960
+480
+100% +$31.1K 0.01% 254
2013
Q3 		$30K Sell
480
-21,200
-98% -$1.36M 0.01% 206
2013
Q2 		$1.35M Buy
+21,680
New +$1.38M 0.65% 33

Other funds holding GSK

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
JEST
JTC Employer Solutions Trustee St Helier, Jersey $1.25B AUM 41.83% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Summit Securities Group's GSK Position: Q2 2026 in Review

Summit Securities Group reduced its GSK (GSK) stake by 67% in Q2 2026, selling an estimated $10.6K and leaving 100 shares worth $5.24K. The position accounts for ﹤0.01% of the portfolio, ranked #967.

Summit Securities Group first reported a position in GSK in Q2 2013 and has held it in 37 quarters since. The position peaked at $1.97M in Q4 2019. 1,037 funds tracked by Wall St. Rank hold GSK as of Q2 2026.

  • Summit Securities Group held 100 shares of GSK worth $5.24K as of Q2 2026.
  • Summit Securities Group sold 200 GSK shares in Q2 2026, an estimated $10.6K.
  • GSK made up ﹤0.01% of Summit Securities Group's portfolio in Q2 2026, its #967 holding.
  • Summit Securities Group first reported a position in GSK in Q2 2013 and has held it in 37 quarters since.
  • Summit Securities Group's GSK position peaked at $1.97M in Q4 2019.
  • 1,037 funds tracked by Wall St. Rank held GSK as of Q2 2026.

Based on Summit Securities Group's 13F filing for Q2 2026, filed 3 Aug 2026.